Interpace Z Score

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Please see Interpace Biosciences Piotroski F Score and Interpace Biosciences Valuation analysis.
  
Interpace Biosciences Invested Capital Average is projected to increase significantly based on the last few years of reporting. The past year's Invested Capital Average was at 11.06 Million. The current year Market Capitalization is expected to grow to about 33.2 M, whereas Return on Invested Capital is forecasted to decline to (1.48) . Interpace Biosciences Cost of Revenue is projected to decrease significantly based on the last few years of reporting. The past year's Cost of Revenue was at 23.37 Million. The current year Interest Expense is expected to grow to about 718.9 K, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to (16.3 M).

Interpace Z Score Analysis

Interpace Biosciences' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2019 2020 2021 2022 (projected)
Interest Expense440 K549 K496 K718.95 K
Gross Profit8.33 M10.72 M17.95 M15.16 M
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis

Current Interpace Biosciences Z Score

    
  -2.8  
Most of Interpace Biosciences' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )

Interpace Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Interpace Biosciences is extremely important. It helps to project a fair market value of Ford otc stock properly, considering its historical fundamentals such as Z Score. Since Interpace Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Interpace Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Interpace Biosciences' interrelated accounts and indicators.
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

According to the company's disclosures, Interpace Biosciences has a Z Score of -2.8. This is 141.48% lower than that of the Health Care Providers & Services sector and 184.08% lower than that of the Health Care industry. The z score for all United States stocks is 132.11% higher than that of the company.

Interpace Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.
Interpace Biosciences is currently under evaluation in z score category among related companies.

Interpace Biosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Interpace Biosciences from analyzing Interpace Biosciences' financial statements. These drivers represent accounts that assess Interpace Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Interpace Biosciences' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(136.22 K)(162.88 K)(136.96 K)(150.15 K)(172.68 K)(186.31 K)
Revenue Per Employee213.92 K211.96 K246.02 K135.28 K121.75 K132.3 K
Average Assets51.18 M46.35 M57.73 M54.44 M41.44 M51.19 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(5.93 M)(12.3 M)(11.66 M)(26.17 M)(30.09 M)(32.47 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(8.49 M)(8.55 M)(21.8 M)(20.35 M)(9.74 M)(10.51 M)
Earnings before Tax(12.61 M)(12.69 M)(26.77 M)(26.4 M)(15.61 M)(16.84 M)
Average Equity34.29 M32.45 M21.43 M(19.48 M)(37.44 M)(38.42 M)
Enterprise Value15.68 M14.87 M23.28 M4.92 M38.78 M41.84 M
Free Cash Flow(15.29 M)(9.12 M)(19.07 M)(15.55 M)(9.03 M)(9.75 M)
Invested Capital(2.8 M)3.85 M13.24 M7.83 M16.31 M17.59 M
Invested Capital Average(4.2 M)2.51 M12.24 M11.56 M11.06 M11.93 M
Market Capitalization27.39 M22.88 M19.1 M12.69 M31.18 M33.16 M
Tangible Asset Value20.49 M18.59 M27.26 M25.9 M22.71 M28.4 M
Working Capital11.72 M9.05 M(782 K)(4.11 M)(3.52 M)(3.61 M)

Interpace Fundamentals

About Interpace Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Interpace Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Interpace Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Interpace Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Interpace Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Efficient Frontier Now

   

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Interpace Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Interpace Biosciences Piotroski F Score and Interpace Biosciences Valuation analysis. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for analysis

When running Interpace Biosciences price analysis, check to measure Interpace Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Biosciences is operating at the current time. Most of Interpace Biosciences' value examination focuses on studying past and present price action to predict the probability of Interpace Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Interpace Biosciences' price. Additionally, you may evaluate how the addition of Interpace Biosciences to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Please note, there is a significant difference between Interpace Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Interpace Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Interpace Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.